help button home button Endocrine Society Molecular Endocrinology ENDO 08 Sessions Library
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Molecular Endocrinology, doi:10.1210/me.2006-0146
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow NURSA Molecule Pages Link
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Avallone, R.
Right arrow Articles by Tremblay, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Avallone, R.
Right arrow Articles by Tremblay, A.
Molecular Endocrinology 20 (12): 3165-3178
Copyright © 2006 by The Endocrine Society

A Growth Hormone-Releasing Peptide that Binds Scavenger Receptor CD36 and Ghrelin Receptor Up-Regulates Sterol Transporters and Cholesterol Efflux in Macrophages through a Peroxisome Proliferator-Activated Receptor {gamma}-Dependent Pathway

Roberta Avallone1, Annie Demers1, Amélie Rodrigue-Way, Kim Bujold, Diala Harb, Silvia Anghel, Walter Wahli, Sylvie Marleau, Huy Ong and André Tremblay

Faculty of Pharmacy (R.A., A.D., K.B., D.H., S.M., H.O.), Pavillon Jean-Coutu, University of Montreal, Montréal, Québec, H3C 3J7 Canada; Research Center, Ste-Justine Hospital (R.A., A.D., A.R.-W., A.T.), and Departments of Biochemistry (A.R.-W., A.T.), and Obstetrics and Gynecology (A.T.), Faculty of Medicine, University of Montreal, Montreal, Québec, H3T 1C5 Canada; and Center for Integrative Genomics and National Center of Competence in Research Frontiers in Genetics (S.A., W.W.), University of Lausanne, CH-1015 Lausanne, Switzerland

Address all correspondence and requests for reprints to: André Tremblay, Research Center, Ste-Justine Hospital, 3175 Côte Ste-Catherine, Montréal (Québec), Canada H3T 1C5. E-mail: andre.tremblay{at}recherche-ste-justine.qc.ca; or Huy Ong, Pavillon Jean-Coutu, University of Montreal, Montréal (Québec), Canada H3C 3J7. E-mail: huy.ong{at}umontreal.ca.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 RESULTS
 DISCUSSION
 MATERIALS AND METHODS
 REFERENCES
 
Macrophages play a central role in the pathogenesis of atherosclerosis by accumulating cholesterol through increased uptake of oxidized low-density lipoproteins by scavenger receptor CD36, leading to foam cell formation. Here we demonstrate the ability of hexarelin, a GH-releasing peptide, to enhance the expression of ATP-binding cassette A1 and G1 transporters and cholesterol efflux in macrophages. These effects were associated with a transcriptional activation of nuclear receptor peroxisome proliferator-activated receptor (PPAR){gamma} in response to binding of hexarelin to CD36 and GH secretagogue-receptor 1a, the receptor for ghrelin. The hormone binding domain was not required to mediate PPAR{gamma} activation by hexarelin, and phosphorylation of PPAR{gamma} was increased in THP-1 macrophages treated with hexarelin, suggesting that the response to hexarelin may involve PPAR{gamma} activation function-1 activity. However, the activation of PPAR{gamma} by hexarelin did not lead to an increase in CD36 expression, as opposed to liver X receptor (LXR){alpha}, suggesting a differential regulation of PPAR{gamma}-targeted genes in response to hexarelin. Chromatin immunoprecipitation assays showed that, in contrast to a PPAR{gamma} agonist, the occupancy of the CD36 promoter by PPAR{gamma} was not increased in THP-1 macrophages treated with hexarelin, whereas the LXR{alpha} promoter was strongly occupied by PPAR{gamma} in the same conditions. Treatment of apolipoprotein E-null mice maintained on a lipid-rich diet with hexarelin resulted in a significant reduction in atherosclerotic lesions, concomitant with an enhanced expression of PPAR{gamma} and LXR{alpha} target genes in peritoneal macrophages. The response was strongly impaired in PPAR{gamma}+/– macrophages, indicating that PPAR{gamma} was required to mediate the effect of hexarelin. These findings provide a novel mechanism by which the beneficial regulation of PPAR{gamma} and cholesterol metabolism in macrophages could be regulated by CD36 and ghrelin receptor downstream effects.


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
RESULTS
 DISCUSSION
 MATERIALS AND METHODS
 REFERENCES
 
MACROPHAGES PLAY A key role in the early events of atherogenesis by accumulating cholesteryl ester and oxidized derivatives through increased uptake of oxidized low-density lipoprotein (oxLDL) by scavenger receptors such as CD36, thereby contributing to excessive lipid loading and atherogenic formation of foam cells. In addition to initiating a proinflammatory response in monocytes/macrophages, such internalization of oxLDL by CD36 provides a source of oxidized fatty acids and oxysterols that serve as endogenous ligands for the respective activation of the nuclear receptors peroxisome proliferator-activated receptor (PPAR) and liver X receptor (LXR) (1, 2).

The identification of several natural ligands, such as prostanoid derivatives and polyunsaturated and oxidized forms of fatty acids, have depicted all three isoforms of PPARs as important metabolic fatty acid sensors (3). Of these, PPAR{gamma} is highly expressed in macrophages, and studies using synthetic PPAR{gamma} ligands of the thiazolidinedione family have provided a role for PPAR{gamma} in exerting antiatherogenic effects in animal models of atherosclerosis (4, 5, 6). PPAR{gamma} was shown to increase in a positive feedback fashion the expression of scavenger receptor CD36, an effect strongly associated with excessive lipid accumulation and macrophage foam cell formation (7, 8). However, PPAR{gamma} activation also produces opposite effects by promoting the expression of LXR{alpha}, which, upon activation by endogenous ligands such as oxysterols, induces the expression of genes involved in peripheral cholesterol efflux and transport from macrophages, such as apolipoprotein E (apoE) and ATP-binding cassette transporters ABCA1 and ABCG1 (1, 2, 9, 10). The metabolic cascade involving PPAR{gamma} and LXR{alpha} is therefore proposed as an attempt by the macrophage to enhance its ability to remove oxLDL from the vessel wall and shunt free cholesterol into the reverse cholesterol transport pathway, thus providing a protective effect against plaque formation in vivo. Hence, interfering with the balance between macrophage lipid uptake and efflux would be predicted to influence atherosclerotic lesion formation.

The GH-releasing peptides (GHRPs) belong to a class of small synthetic peptides known to stimulate GH release through binding to the GH secretagogue-receptor 1a (GHS-R1a), a G protein-coupled receptor originally identified in hypothalamus and pituitary (11). The endogenous ligand of GHS-R1a was later recognized as ghrelin, a 28-amino-acid peptide primarily expressed in the mucosal layer of the stomach but also in several other tissues (12). The peripheral distribution of GHS-R1a in tissues such as heart, adrenals, fat, prostate, and bone has supported physiological roles of ghrelin and GHRPs not exclusively linked to GH release. For example, GH-independent effects on orexigenic properties, fat metabolism, bone cell differentiation, and hemodynamic control have been reported for ghrelin and GHRPs (13, 14). Also, in conditions in which GH release was not promoted or in GH-deficient animals, the GHRP hexarelin was shown to feature cardioprotective effects by preventing ventricular dysfunction (15, 16) and by protecting the heart from damages induced by postischemic reperfusion (17). Our recent findings demonstrating that hexarelin serves as a ligand for CD36 receptor in myocardium (18), and that it interferes with the binding of oxLDL by sharing the same interaction site on CD36 (19), have prompted us to evaluate the ability of hexarelin to modulate macrophage cholesterol metabolism.

Here, we demonstrate that hexarelin promotes cholesterol efflux from macrophages through the enhanced expression of LXR{alpha} and ABC transporters, an effect severely impaired in treated peritoneal macrophages isolated from PPAR{gamma} heterozygote mice, implying an essential role for PPAR{gamma} in mediating the response to hexarelin. The interaction of hexarelin with GHS-R1a, and to a lesser extent with CD36, resulted in transcriptional activation of PPAR{gamma}, an effect also observed with ghrelin, the endogenous ligand of GHS-R1a. Using apoE-null mice, we show that the beneficial effect of hexarelin on macrophage cholesterol metabolism also occurred in vivo with a significant reduction in atherosclerotic lesions in treated mice. These findings therefore support a regulatory pathway by which CD36- and GHS-R1a-mediated effects may translate into antiatherosclerotic properties.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
DISCUSSION
 MATERIALS AND METHODS
 REFERENCES
 
Hexarelin Reduces Lipid Accumulation and Increases Cholesterol Efflux in Human THP-1 Macrophages
Human monocytic THP-1 cells were differentiated into adherent macrophage-like cells by the addition of phorbol myristate acetate (PMA) and were tested for CD36 and GHS-R1a mRNA and protein expression (Fig. 1AGo). To determine whether hexarelin could modulate the scavenging function of CD36 to internalize oxLDL into macrophages, THP-1 cells were incubated with oxLDL to promote lipid accumulation and were then treated with hexarelin. As determined by staining neutral lipids with Oil red O, the increase in size and number of lipid vesicles upon oxLDL loading was markedly diminished by treating cells with hexarelin (Fig. 1BGo). Hexarelin reduced the lipid loading in a significant and dose-dependent manner with a respective 23% and 40% decrease at 10–7 and 10–5 M hexarelin (Fig. 1CGo), suggesting that hexarelin prevents lipid accumulation from oxLDL uptake in THP-1 cells. Loading macrophages with oxLDL is known to provide the necessary ligands that promote PPAR{gamma} activation and cholesterol removal (8, 9). To test whether hexarelin by itself could promote cholesterol removal from macrophages, THP-1 cells were labeled with tritiated cholesterol and efflux of cholesterol was monitored in absence of oxLDL. As shown in Fig. 1DGo, treatment of THP-1 cells with 10–7 M hexarelin resulted in a significant 30% increase in cholesterol efflux to extracellular high-density lipoprotein (HDL) acceptors, compared with untreated cells.


Figure 1
View larger version (41K):
[in this window]
[in a new window]
  		Fig. 1. Effects of Hexarelin on Lipid Accumulation and Cholesterol Efflux in Human THP-1 Macrophages

A, RNA and protein levels of CD36 and GHS-R1a receptors were measured in predifferentiated and PMA-differentiated THP-1 cells. B, Representative images of differentiated THP-1 cells incubated with 50 µg/ml oxLDL for 24 h in the presence or absence of 10–7 M hexarelin. Lipids were stained with Oil red O. C, THP-1 cells were incubated for 24 h with hexarelin and/or 50 µg/ml oxLDL as indicated. Lipids were stained with Oil red O, extracted, and quantified by photometry. Data are presented as mean ± SEM of at least three separate experiments. *, P < 0.02; and **, P < 0.01 vs. controls. D, Hexarelin promotes cholesterol efflux from THP-1 cells. THP-1 cells were loaded with 3H-cholesterol and incubated with vehicle or 10–7 M hexarelin. Efflux was measured 16 h after addition of 50 µg/ml HDL acceptors. Data are presented as the percentage (±SEM) of efflux relative to the total radioactivity in the cells and medium calculated from three independent experiments. *, P < 0.02.

 
Hexarelin Increases the Metabolic PPAR{gamma}-LXR{alpha}-ABC Pathway in THP-1 Macrophages
To evaluate the cellular mechanism by which cholesterol is removed from macrophages treated with hexarelin, we measured the expression of components of the PPAR-LXR-ABC pathway described to be involved in cholesterol efflux (9). Although differentiating THP-1 into macrophage-like cells with PMA contributed to increase the expression of PPAR{gamma} and LXR{alpha}, higher mRNA levels were consistently measured for PPAR{gamma} and LXR{alpha} after treatment of THP-1 cells with hexarelin, reaching, respectively, a 5.4- and 3.3-fold increases at the 48-h treatment period, which correspond to 2.5- and 1.9-fold increases when normalized to untreated differentiated cells (Fig. 2Go, A and B). Consistent with these changes, we also measured a 1.9- and a 3.2-fold increase in expression levels of, respectively, ABCA1 and ABCG1 in differentiated cells. These results indicate that hexarelin can induce the expression of components of the PPAR{gamma}-LXR{alpha}-ABC pathway in THP-1 macrophages. Similarly, the expression of apoE, also described as an LXR target (10) with ABCA1 and ABCG1, was significantly increased under the same conditions. To ascertain whether these effects correlated with increases in protein levels, we observed by Western analysis a marked increase in PPAR{gamma}, LXR{alpha}, and transporters ABCA1 and ABCG1 protein levels upon treatment of cells for 24 and 48 h with hexarelin (Fig. 2CGo). Consistent with our data on cholesterol efflux, these results indicate that THP-1 macrophages respond to hexarelin by increasing the expression of key markers involved in cholesterol removal.


Figure 2
View larger version (52K):
[in this window]
[in a new window]
  		Fig. 2. Hexarelin Stimulates the PPAR{gamma}-LXR{alpha}-ABC Pathway in THP-1 Macrophages

A, RT-PCR analysis from THP-1 cells treated or not with 10–7 M hexarelin for 48 h. Representative images of mRNA expression are shown for the indicated genes. B, Time study of THP-1 cells treated with 10–7 M hexarelin. Relative amounts of mRNA for the indicated genes were quantified by densitometry. Data are presented as relative fold changes (±SEM) compared with undifferentiated cells, obtained from three to four separate experiments. C, Representative Western analysis of THP-1 cells treated with 10–7 M hexarelin.

 
Hexarelin Signals to Promote PPAR{gamma} Transcriptional Activity
To determine whether the up-regulation of PPAR{gamma} and LXR{alpha} downstream targets in response to hexarelin was dependent upon PPAR{gamma} activity in macrophages, we tested the effect of the highly selective PPAR{gamma} inhibitor GW9662. We found that the increases in protein levels of PPAR{gamma}, LXR{alpha}, and ABCG1 in THP-1 cells treated with 10–7 M hexarelin were completely abrogated in the presence of increasing doses of GW9662 (Fig. 3AGo). ABCA1 protein levels were also diminished but not to basal levels, suggesting a residual regulation by possibly other PPAR isoforms, as opposed to ABCG1, which was found to be more dependent on PPAR{gamma} (20). Our data therefore suggest that the transcriptional activation of PPAR{gamma} is necessary to mediate the effects of hexarelin. To further elucidate whether hexarelin could signal to activate PPAR{gamma} in macrophages, we used a cell reporter luciferase assay to directly assess PPAR{gamma} activity. Murine RAW264.7 macrophages, which express both CD36 and GHS-R1a receptors (data not shown), were transfected with a Gal4-PPAR{gamma} expression plasmid in the presence of a UAStkLuc reporter containing the luciferase gene under the control of a Gal4 response element. As a control, treatment of transfected cells with the PPAR{gamma}-selective ligand troglitazone resulted in a 2.1-fold increase in PPAR{gamma} activity, whereas similar activation levels were also observed upon treatment with 10–7 and 10–5 M hexarelin, suggesting that hexarelin could promote PPAR{gamma} activity in macrophages (Fig. 3BGo). Because hexarelin has the potential to act through CD36 and/or GHS-R1a, we evaluated the ability of hexarelin to activate PPAR{gamma} through each receptor using human 293 cells, which do not express either receptor. We found that, although transfection of 293 cells with either CD36 or GHS-R1a expression plasmid did not result in activation of PPAR{gamma}, addition of 10–7 M hexarelin contributed to increase PPAR{gamma} activity (Fig. 3CGo), suggesting that both receptors needed to be activated to signal to PPAR{gamma}. In addition, these effects were shown to be additive because expression of CD36 and GHS-R1a together conferred a stronger activation of PPAR{gamma}. Similarly, the potential of CD36 and GHS-R1a to translate the effects of hexarelin on PPAR{gamma} activity was also monitored using a PPREtkLuc reporter in cells transiently expressing PPAR{gamma} and RXR{alpha}. As shown in Fig. 3DGo, treating transfected 293 cells with increasing doses of hexarelin enhanced PPAR{gamma} activity in the presence of either CD36 or GHS-R1a, suggesting that expression of either receptor was necessary to mediate the activation of PPAR{gamma} by hexarelin. Given such agonist-independent activation of PPAR{gamma}, we also tested the response of the other PPAR isoforms to hexarelin signaling. Similar to what we observed for PPAR{gamma}, both PPAR{alpha} and PPARß/{delta} were activated in cells expressing GHS-R1a and treated with hexarelin (Fig. 3EGo). However, using the same conditions, no significant activation of LXR{alpha} or LXRß was observed in response to hexarelin. These data suggest that activation of GHS-R1a by hexarelin results in the selective activation of PPAR isoforms, without directly modulating LXR activity.


Figure 3
View larger version (40K):
[in this window]
[in a new window]
  		Fig. 3. Hexarelin Signals to Activate PPAR{gamma}

A, Inhibition of PPAR{gamma} activity impairs the increase in LXR{alpha}, ABCA1, and ABCG1 protein levels by hexarelin. PMA-differentiated THP-1 cells were treated with 10–7 M hexarelin and with 1 and 5 µM of the PPAR{gamma} inhibitor GW9662 for 48 h and analyzed by Western blot. B, Murine RAW264.7 macrophage cells were transfected with the expression plasmid coding for Gal4-PPAR{gamma} in the presence of the reporter gene UAStkLuc. Cells were then treated with 1 µM troglitazone (Tro) or hexarelin for 16 h before harvest. Results are expressed as fold changes in luciferase activity compared with untreated cells, determined from duplicates from at least three independent experiments. C, Activation of PPAR{gamma} by hexarelin through CD36 and GHS-R1a receptors. Human 293 cells were transfected with Gal4-PPAR{gamma} plasmid and UAStkLuc reporter, and treated with 10–7 or 10–5 M hexarelin for 16 h before harvest. Cells were cotransfected with CD36 and/or GHS-R1a expression plasmid as indicated. Normalized reporter activity was determined and presented as fold change ± SEM compared with untreated cells set at 1.0. D, Activation of PPAR{gamma} by hexarelin is dose dependent. 293 cells were transfected with a PPREtkLuc reporter and expression vectors for PPAR{gamma} and RXR{alpha} in the absence (open circle) or presence of a plasmid coding for GHS-R1a (filled circles) or CD36 (open squares). After transfection, cells were treated with increasing doses of hexarelin and harvested for luciferase activity. Each point represents the percentage changes (mean ± SEM) compared with untreated cells set at 100%. E, Hexarelin can promote the activity of PPARs but not LXRs. 293 cells were transfected with Gal4 fusions of PPAR or LXR isoforms as indicated, in the presence of the UAStkLuc reporter and GHS-R1a plasmid. Cells were treated with receptor ligands or hexarelin for 16 h before harvest for luciferase activity. Ligands used are WY14643 (1 µM) for PPAR{alpha}, carbacyclin (1 µM) for PPAR{delta}, and 22R-hydroxycholesterol (5 µM) for LXRs. Results are expressed as in B.

 
The Activation of PPAR{gamma} through GHS-R1a Activation Is Activation Function (AF)-1 Dependent
The transcriptional ability of most nuclear receptors to regulate gene expression is dependent upon their AF-1 and AF-2 domain activity. Although AF-2 activity is triggered by ligand binding to promote coregulator recruitment, it is also recognized that receptor AF-1 activity can mediate transcriptional activation in response to intracellular signaling transduction pathways. Our results on the activation of PPAR{gamma} by hexarelin through the GHS-R1a receptor suggest that PPAR{gamma} activity might be under the control of such intracellular signaling by GHS-R1a. To determine whether AF-1 activity is involved in the PPAR{gamma} response to GHS-R1a activation, we generated a Gal4-ABCD{gamma} [amino acids (aa) 1–254] truncated version of hPPAR{gamma}, in which the entire ligand binding domain was deleted. As shown in Fig. 4AGo, using 293 cells transfected with GHS-R1a, hexarelin contributed to increase the Gal4-ABCD{gamma} activity to a similar extent as the full-length PPAR{gamma}. The activation levels of the ABCD{gamma} construct in response to hexarelin were dose dependent in GHS-R1a-expressing cells (Fig. 4BGo). These data therefore suggest a role of AF-1 in the regulation of PPAR{gamma} activity through GHS-R1a activation by hexarelin.


Figure 4
View larger version (36K):
[in this window]
[in a new window]
  		Fig. 4. GHS-R1a-Dependent Transactivation of PPAR{gamma} by Hexarelin Is Ligand-Independent

A, Hexarelin promotes PPAR{gamma} AF-1 activity. Human 293 cells were transfected with Gal4 fusions of full-length PPAR{gamma} or a ligand binding domain-truncated ABCD{gamma} (aa 1–254) and the UAStkLuc reporter in the presence or absence of GHS-R1a. After transfection, cells were treated with 10–7 M hexarelin or left untreated for 16 h before harvest. Results are expressed as fold changes compared with untreated cells, which were arbitrarily set at 1.0 for each PPAR{gamma} construct. B, Dose response of cells transfected with Gal4-ABCD{gamma} and treated with increasing concentrations of hexarelin as indicated. Cells were either mock transfected (open circles) or transfected (filled circles) with a GHS-R1a plasmid. Each point represents the percentage changes (mean ± SEM) compared with untreated cells set at 100%. C, Hexarelin promotes PPAR{gamma} phosphorylation in THP-1 macrophages. THP-1 cells were differentiated, serum-deprived, and treated with hexarelin for the indicated time. Cell extracts were immunoprecipitated with an antibody against PPAR{gamma} and analyzed by Western blot using an antiphosphoserine antibody. PPAR{gamma} content was also monitored by Western analysis.

 
Hexarelin Promotes Phosphorylation of PPAR{gamma} in THP-1 Macrophages
Posttranslational modification such as phosphorylation is well known to regulate the AF-1 activity of many nuclear receptors, including PPAR{gamma} (21). Given our results on the effects of hexarelin to regulate the AF-1 activity of PPAR{gamma}, we next determined whether hexarelin could modulate the phosphorylation of PPAR{gamma}. Using differentiated THP-1 macrophages, we found an increase in serine phosphorylation of PPAR{gamma} in response to hexarelin treatment, as determined by immunoprecipitation of endogenous PPAR{gamma} and Western analysis using an antiphosphoserine antibody (Fig. 4CGo). Such enhanced PPAR{gamma} phosphorylation was readily observed after 5 min of treatment with hexarelin and in a dose-dependent manner, as compared with untreated cells, indicating that hexarelin may induce kinase activation within that period.

Hexarelin Differently Affects the Expression and Promoter Occupancy of CD36 and LXR{alpha} Genes by PPAR{gamma} in THP-1 Cells
Given the potential role of GHS-R1a and CD36 receptors to transduce the effect of hexarelin in macrophages, we wished to determine whether their expression was modulated under these conditions. The mRNA and protein levels of GHS-R1a were not significantly modified in differentiated THP-1 cells treated with hexarelin (Fig. 5Go, A and B), indicating that GHS-R1a expression was apparently not under the regulation of PPAR{gamma}. In the same conditions, CD36 expression was also not affected by hexarelin, with a slight decrease in mRNA levels and no change in its protein steady-state levels. The expression of SR-A, another scavenger receptor that mediates internalization of modified LDL, also remained unaffected, suggesting that macrophages treated with hexarelin may not result in enhanced lipid uptake through CD36 and SR-A scavenger receptors. The apparent down-regulation in CD36 mRNA levels was rather surprising because CD36 has been described to be up-regulated by ligands of PPAR{gamma} in macrophages (7, 8). To further investigate the mechanism by which this unexpected regulation of CD36 by hexarelin may result, we performed chromatin immunoprecipitation (ChIP) assay to assess the relative occupancy by PPAR{gamma} onto the promoter region of the CD36 gene, in comparison with LXR{alpha}, which, in contrast to CD36, was up-regulated in THP-1 cells treated with hexarelin (Fig. 2Go, A and B). The CD36 and LXR{alpha} promoters were described to contain each a functional PPAR response element (PPRE) that mediates their enhanced expression by PPAR{gamma} ligands (7, 22). After treatment of THP-1 cells, chromatin was immunoprecipitated using an anti-PPAR{gamma} antibody, and the relative amount of the CD36 and LXR{alpha} promoter region that contains the PPRE was assessed by PCR using specific primers, as depicted in Fig. 5CGo. As predicted, both CD36 and LXR{alpha} promoters were found to be occupied by PPAR{gamma} in a greater extent in response to the PPAR{gamma} agonist troglitazone. We also obtained a similar rise in the occupancy of LXR{alpha} promoter in cells treated with hexarelin, indicating that LXR{alpha} up-regulation by hexarelin may result from a preferred recruitment of PPAR{gamma} to the LXR{alpha} promoter. However, the occupancy of the promoter region of CD36 by PPAR{gamma} was slightly diminished in response to hexarelin (Fig. 5CGo), consistent with the changes in CD36 mRNA expression. These findings suggest a selective mechanism used to differently regulate PPAR{gamma}-targeted genes in response to hexarelin.


Figure 5
View larger version (58K):
[in this window]
[in a new window]
  		Fig. 5. The Expression of CD36 and GHS-R1a Is Not Increased by Hexarelin in THP-1 Macrophages

A, THP-1 cells were treated with 10–7 M hexarelin for 48 h and analyzed for GHS-R1a, CD36, and SR-A expression by RT-PCR. Glyceraldehyde-3-phosphate dehydrogenase expression was used as a loading control. B, Representative Western analysis of GHS-R1a and CD36 receptors in THP-1 cells treated as in A. ß-Actin was used as a loading control. C, ChIP analysis of PPAR{gamma} recruitment to CD36 and LXR{alpha} promoters in response to hexarelin. THP-1 cells treated with troglitazone (Tro) or hexarelin for 3 h were subjected to ChIP analysis using an antibody against PPAR{gamma}. PCR was performed on immunoprecipitated DNA from samples and on total DNA extracted (input), using pairs of primers that cover the PPRE-containing regions of CD36 and LXR{alpha} gene promoters as shown. The fold changes compared with untreated THP-1 cells represent the mean of two independent experiments.

 
In Vivo Activation of the PPAR{gamma}-LXR{alpha}-ABC Pathway in Peritoneal Macrophages from Mice Treated with Hexarelin
Concurrent with our findings that hexarelin can promote activation of the PPAR-LXR-ABC cascade in cultured THP-1 macrophages, we next addressed the question as to whether hexarelin might promote similar effects in vivo using apoE-null mice, which have been widely studied for the development of atherosclerosis, because they develop spontaneous atherosclerotic lesions and fibrous plaques at the aortic root and branch points, similar to what occurs in human atherosclerosis (23, 24). We therefore maintained apoE–/– mice on a high-fat, high-cholesterol diet for 12 wk, a condition known to promote atherosclerotic plaque formation, and then we treated them daily with either saline or hexarelin. The concentration of 100 µg/kg·d hexarelin used in our study was reported to not elicit GH release and therefore prevented any undesired effects of GH (Ref. 16 and data not shown). Chronic treatment of mice with hexarelin did not significantly change their weight and food intake, and no adverse health problems were noticed throughout the study. We measured a 10% decrease in total cholesterol and a 33% increase in HDL-associated cholesterol in hexarelin-treated mice (data not shown), which suggests that although these changes did not reach statistical significance, hexarelin is likely to promote circulating cholesterol into the HDL fraction. Plasma triglycerides were not affected, indicating that hexarelin did not induce hypertriglyceridemia, as is often observed with the use of LXR ligands (2). To further assess the effect of hexarelin in vivo, we observed that macrophages collected from the peritoneal cavity of apoE–/– mice fed a cholesterol-rich diet and treated with hexarelin had a reduced ability to accumulate lipids in response to oxLDL loading compared with controls (Fig. 6AGo). More noticeably, we found that these changes were accompanied by an increase in the expression of PPAR{gamma} (7.5-fold), LXR{alpha} (2.9-fold), ABCA1 (1.9-fold), and ABCG1 (1.5-fold) in oxLDL-loaded macrophages from mice treated with hexarelin compared with the saline group (Fig. 6BGo). In the same conditions, a slight decrease in CD36 expression was observed, whereas expression of SR-A and GHS-R1a remained unchanged. To preclude any undesired effects of the apoE-null phenotype and also to avoid possible activation of PPAR and LXR by exogenous ligands provided with loading of oxLDL, we performed RT-PCR analysis on macrophages collected from wild-type C57Bl/6 mice (i.e. the same genetic background as the apoE-null), without prior activation with oxLDL. In these conditions, maximal increases for PPAR{gamma} (2.8-fold), LXR{alpha} (1.8-fold), ABCA1 (2.4-fold), ABCG1 (2.1-fold), and apoE (2.4-fold) were obtained in macrophages treated with hexarelin compared with control, whereas CD36 expression remained unaffected (Fig. 6CGo). These changes also correlated with protein levels, notably for LXR{alpha} and ABCG1 (Fig. 6DGo). These findings are consistent with the expression profile seen in THP-1 cells (Figs. 2AGo and 5AGo) and also indicate that the macrophage PPAR{gamma}-LXR{alpha}-ABC pathway could be activated in vivo by hexarelin. Using isolated macrophages from apoE-null mice, we found that the cholesterol efflux was significantly increased in cells treated with hexarelin compared with untreated cells (Fig. 6EGo). Although the use of peritoneal macrophages may not truly reflect the actions of artery wall macrophages, these results suggest that hexarelin may be sufficient by itself to favor protective mechanisms within macrophages through activation of the PPAR-LXR-ABC pathway and cholesterol removal.


Figure 6
View larger version (39K):
[in this window]
[in a new window]
  		Fig. 6. Activation of the PPAR{gamma}-LXR{alpha}-ABCA1/G1 Pathway in Peritoneal Macrophages and Reduction of Atherosclerotic Lesions in apoE-Null Mice Treated with Hexarelin

A, Representative images of Oil red O-stained peritoneal macrophages from apoE–/– mice kept on a high-fat, high-cholesterol diet for 6 wk and treated with daily sc injections of 0.9% NaCl or 100 µg/kg·d hexarelin. Thioglycolate-elicited macrophages were collected from treated mice and incubated in vitro with oxLDL before lipid staining. B, Enhanced PPAR{gamma}-LXR{alpha}-ABC pathway in peritoneal macrophages from apoE–/– mice treated with hexarelin. apoE-null mice were treated as in A, and peritoneal macrophages were collected after injection of oxLDL or saline and subjected to RT-PCR analysis for the indicated genes. C, Hexarelin promotes the PPAR{gamma}-LXR{alpha}-ABC pathway in C57Bl/6 mouse peritoneal macrophages. Macrophages were collected from C57Bl/6 mice maintained on a standard diet and treated in culture with increasing amounts of hexarelin for 24 h. Cells were harvested and RT-PCR analysis was performed as in B. D, Macrophages were isolated and treated as in C and harvested for Western analysis. E, Hexarelin increases cholesterol removal from mouse macrophages. Cholesterol efflux to HDL was determined in peritoneal macrophages collected from apoE-null mice and incubated for 16 and 24 h with 10–7 M hexarelin or vehicle. Also shown are the basal rates without HDL acceptors. Data are presented as the percentage (±SEM) of efflux relative to the total radioactivity in the cells and medium calculated from four independent experiments. *, P < 0.05 vs. respective controls. F, Reduction of atherosclerotic lesions in apoE-null mice fed a high-fat, high-cholesterol diet for 12 wk and treated with hexarelin as compared with mice treated with saline. The entire aortic root was dissected and stained for lipids using Oil red O for en face analysis. G, Quantification of aortic tree lesion area in mice treated with hexarelin compared with controls. Aortic surface covered by Oil red O-stained lesions was quantified and expressed as a percent of the total aortic area. *, P < 0.01 vs. controls.

 
Hexarelin Protects apoE-Null Mice from Developing Atherosclerotic Lesions
We next addressed the question of whether the response of macrophages to hexarelin could correlate with a beneficial effect on plaque formation induced in apoE-null mice maintained on a lipid-rich diet for 12 wk. En face analysis of aortic tree sections stained with Oil red O showed a significant reduction of 28% in atherosclerotic lesions in hexarelin-treated mice compared with controls (Fig. 6Go, F and G). These results demonstrate that hexarelin could reduce plaque formation in an animal model of atherosclerosis.

PPAR{gamma} Is Fully Required to Mediate the Response to Hexarelin in Peritoneal Macrophages
The complete disruption of the PPAR{gamma} gene causes embryonic lethality in mice and therefore precludes obtaining mature macrophages that lack PPAR{gamma} (25, 26). To partly circumvent this, we isolated macrophages from genetically altered PPAR{gamma}+/– mice, which are viable and show an impaired PPAR{gamma} function (27), and performed expression analysis in response to hexarelin. We observed that mRNA levels of LXR{alpha}, ABCA1, ABCG1, and apoE, all shown to be potently up-regulated in wild-type macrophages, remained mostly unaffected (fold increases ranged from 0.8–1.4) in PPAR{gamma}+/– macrophages treated with hexarelin (Fig. 7AGo). The protein levels of LXR{alpha} and ABCG1 were also unaffected in treated PPAR{gamma}+/– macrophages (Fig. 7BGo). This impaired response in PPAR{gamma}+/– macrophages strongly supports a functional role for PPAR{gamma} in mediating the effect of hexarelin in macrophages.


Figure 7
View larger version (48K):
[in this window]
[in a new window]
  		Fig. 7. Activation of the LXR{alpha}-ABCA1/G1 Pathway by Hexarelin in Peritoneal Macrophages Is Dependent on PPAR{gamma}

A, The activation of the LXR-ABCA1/G1 pathway by hexarelin is severely impaired in PPAR{gamma}+/– macrophages. Peritoneal macrophages were collected from PPAR{gamma}+/– mice maintained on a standard diet and treated in culture with hexarelin for 24 h. Cells were harvested and RT-PCR analysis was performed from two separate experiments. B, LXR{alpha} and ABCG1 proteins were not increased by hexarelin in PPAR{gamma}+/– macrophages. PPAR{gamma}+/– peritoneal macrophages were collected and treated as in A before being harvested for Western analysis. Equal amounts of proteins were loaded in each well.

 

   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
 DISCUSSION
MATERIALS AND METHODS
 REFERENCES
 
Alterations in the rates of macrophage cholesterol uptake or efflux each have the potential to influence foam cell formation and the development of atherosclerotic lesions. Therefore, an understanding of the regulatory pathways that control cellular lipid flux may identify new opportunities for intervention in the process of lipid disorders. In this study, we demonstrate the ability of scavenger receptor CD36 and ghrelin receptor to enhance PPAR{gamma} transcriptional activity in response to hexarelin, a shared peptide ligand. These effects were associated with an enhanced expression of downstream mediators, such as LXR{alpha}, apoE, and ABCA1 and ABCG1 transporters, that coordinate cholesterol removal from treated mouse macrophages and a significant reduction in plaque formation in apoE-null mice maintained on a high-fat, high-cholesterol diet.

Although activation of PPAR{gamma} by selective agonists was shown to promote beneficial effects in cholesterol removal from macrophages and subsequent plaque reduction in atherosclerotic mice (2), our findings suggest that CD36 and/or GHS-R1a receptors may signal to enhance PPAR{gamma} activity resulting in similar effects on macrophage cholesterol metabolism. As such, given the ability of hexarelin to interfere with oxLDL binding to CD36 (19), thereby lowering the supply in oxidative fatty acids and other potential ligands of PPAR{gamma}, it seems unlikely that activation of PPAR{gamma} by hexarelin would depend on a greater intake of exogenous oxidized lipids by macrophages. In agreement with this, treatment of peritoneal macrophages with hexarelin in absence of oxLDL resulted in an increase of the PPAR{gamma}-LXR{alpha}-ABC pathway, suggesting that hexarelin signaling may be sufficient by itself to activate PPAR{gamma}. In addition, scavenger receptor SR-A, which also mediates modified LDL uptake by macrophages, was not up-regulated by hexarelin. Our observation that CD36 and/or GHS-R1a ligands enhanced PPAR{gamma} activity may therefore rely on more ligand-independent effects. Consistent with this, we observed that activation of GHS-R1a receptor with hexarelin, or its natural ligand ghrelin (unpublished observations), led to activation of a PPAR{gamma} construct missing the ligand binding domain, suggesting that such an effect may translate through activation of PPAR{gamma} AF-1 function. Ligand-independent activation of PPAR{gamma} has been reported to involve receptor posttranslational modifications such as phosphorylation, and our results that hexarelin can promote phosphorylation of PPAR{gamma} in THP-1 cells may therefore provide a basis on how PPAR{gamma} can respond to hexarelin signaling. However, the effects of phosphorylation on PPAR{gamma} activity have been reported to vary, often in opposite directions, given the stimulus, the kinase involved, the modified residue, and the cellular and promoter context (21). For example, PPAR{gamma} activity was enhanced in cells treated with insulin through a MAPK-dependent phosphorylation of its N-terminal region (28, 29, 30). Both ligand-dependent and -independent activation of PPAR isoforms was shown to require PPAR phosphorylation in response to protein kinase A activators (31). Although the signaling events triggered by the interaction of hexarelin with CD36 remain to be defined, CD36 has been shown to interact with the src kinases Lyn and Fyn to initiate downstream activation of MAPKs in response to ligands such as thrombospondin-1 and ß-amyloid (32, 33). Similarly, activation of GHS-R1a by ghrelin was shown to initiate a signaling cascade leading to MAPK activation (34, 35, 36), and the neuroprotective effects of hexarelin in a rat model of neonatal hypoxia-ischemia were correlated with activation of Akt (37). On the other hand, mechanisms related to receptor phosphorylation have also been described to inhibit PPAR{gamma} activity. Phosphorylation of a specific site within its AF-1 domain resulted in an inhibition of ligand-activated PPAR{gamma} and reduced adipocyte differentiation (38, 39, 40). Treatment of THP-1 macrophages with TGFß also resulted in PPAR{gamma} phosphorylation and inhibition with a decreased expression of CD36 (41). Therefore, the exact mechanism(s) by which PPAR{gamma} activity is modulated in response to CD36 and/or GHS-R1a ligands remain to be clearly defined. However, given the ability by which posttranslational modifications such as phosphorylation could regulate PPAR{gamma} transcriptional activity and that ligand-independent recruitment of transcriptional coregulators is favored by nuclear receptor phosphorylation (21, 42), our results suggest that such mechanism may contribute in the cellular response to hexarelin.

It is recognized that CD36 is considered proatherogenic. Studies using CD36-null mice have provided evidence that CD36 might favor atherogenesis (43, 44), and elevated levels of CD36 have been associated with foam cell formation and atherosclerosis in humans (45). Internalization of oxLDL through CD36 is known to provide a source of fatty acid derivatives that promote PPAR{gamma} activation and further increase in CD36 that results in massive entry of lipids in macrophages (1, 7, 8). Unexpectedly, we found that although PPAR{gamma} was activated by hexarelin, the expression of CD36 was not increased in cultured and in peritoneal macrophage cells, as opposed to LXR{alpha}, also described as a direct target for PPAR{gamma} (7, 9). The exact mechanism by which hexarelin exerts such apparent opposite regulation of CD36 and LXR{alpha} expression is not yet clear, but our results suggest that hexarelin signaling might disrupt CD36 up-regulation normally seen upon activation of PPAR{gamma} with ligands. Consistent with these findings, we observed in a ChIP assay a preferred occupancy of the LXR{alpha} promoter by PPAR{gamma}, as opposed to the CD36 promoter, in THP-1 cells treated with hexarelin. Activation of PPAR{gamma} by selective agonists has been shown to differently regulate downstream effectors in macrophage lipid metabolism. For example, troglitazone, in contrast to other PPAR{gamma} ligands, repressed the expression of ABCA1 while increasing CD36 in macrophages, suggesting paradoxical effects on gene expression upon PPAR{gamma} activation (46). More recently, although both PPAR{alpha}- and PPAR{gamma}-selective ligands markedly reduced plaque formation in atherosclerotic mice, they induced an opposite pattern in CD36 expression in isolated peritoneal macrophages of treated mice (20). Clearly, the regulation of CD36 expression may not solely depend on PPAR{gamma} activity, as exemplified in this study and others using PPAR{gamma}-deficient macrophages (46). The potential of hexarelin to lower CD36 expression, as observed in mouse peritoneal macrophages either from treated animals or maintained in culture, was not as significant as in THP-1 cells, suggesting that in vivo other mechanisms might affect CD36 expression. Inflammatory cytokines and growth factors were described to variably regulate CD36 expression in vascular and peritoneal macrophages (47). These effects were reported to involve both transcriptional and posttranscriptional mechanisms, resulting in changes in the intracellular pool and surface expression of CD36 (47, 48). Therefore, we can expect that intracellular signaling triggered by hexarelin and possibly through GHS-R1a may likely be involved in limiting CD36 expression as opposed to PPAR{gamma} ligands. Consistent with this, disruption of insulin receptor signaling was shown to result in a posttranscriptional increase of CD36 in macrophages (49). Our observations that protein levels of CD36 were not significantly changed in macrophages treated with hexarelin or with another GHRP selective for CD36 (44) suggest that the cellular mechanism by which steady-state levels of CD36 are maintained but not increased is likely shared among the GHRP class of peptides. Altogether, the apparent different regulation of PPAR{gamma} targets may provide an interesting potential for hexarelin to up-regulate PPAR{gamma}-dependent activation pathway toward LXR{alpha}, ABC transporters, and cholesterol efflux in macrophages, without increasing CD36 receptor, and therefore limiting its ability to mediate excessive oxLDL uptake, to protect macrophages from becoming foam cells.

The role of the GHS-R1a receptor in atherosclerosis has not been well characterized. GHS-R1a is expressed in a variety of tissues and cell types including macrophages (50). Its natural ligand ghrelin and synthetic GHS were shown to mediate endocrine and nonendocrine activities such as GH release, orexigenic action, cardiovascular and antiproliferative effects, and influence gastroenteropancreatic functions and adipocyte differentiation (13). For example, treatment of rat adipocytes with ghrelin contributed to significantly increase the expression of PPAR{gamma} and adipogenesis (51). More recently, studies have emerged associating GHS-R1a ligands with antiinflammatory function in endothelial cells and macrophages. Both GHRP-2 and ghrelin were shown to prevent the endotoxin-induced release of IL-6 from peritoneal macrophages isolated from adjuvant-induced arthritic rats (52). In addition, ghrelin was reported to inhibit cytokine release and nuclear factor {kappa}B activity in human endothelial cells (53). With studies using PPAR isoform-null macrophages that have outlined the role of PPARs in mediating antiinflammatory processes (54, 55), and given the ability of PPAR ligands to inhibit the expression of inflammatory genes in macrophages and other vascular cells (2), it is tempting to speculate that activation of CD36 and/or GHS-R1a by hexarelin might impact the inflammatory response in macrophages through PPAR{gamma} or other PPAR isoforms. In support of such an expanded role of hexarelin toward all PPAR isoforms, we found that PPAR{alpha} and PPAR{delta}, but not LXR isoforms, were up-regulated, suggesting a selective response of PPARs to hexarelin. In addition, although it is likely that alterations in plasma cholesterol may contribute in part to the beneficial effects of hexarelin, the changes we measured did not obviously reflect the extent of lesion reduction, which may therefore support a role for antiinflammatory pathways in cooperating to the beneficial effects of hexarelin. Clearly, more studies will be needed to address this possibility.

In summary, we describe a novel regulatory pathway to promote the PPAR{gamma}-LXR{alpha}-ABC cascade in macrophages involving interaction with CD36 and ghrelin receptor. Such modulation requires PPAR{gamma} and is associated with enhanced cholesterol efflux by macrophages and reduction of lesions in atherosclerotic mice. Consequently, a detailed knowledge of the concerted modulation of CD36 and ghrelin receptor signaling pathways may help to provide additional strategies in pathologic conditions such as atherosclerosis.


   MATERIALS AND METHODS
TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
 DISCUSSION
 MATERIALS AND METHODS
REFERENCES
 
Cell Culture and Treatments
THP-1 cells were grown in RPMI 1640 supplemented with 10% fetal bovine serum (FBS). Macrophage differentiation was initiated with the addition of 5 ng/ml PMA in culture medium for 48 h. Human embryonic kidney 293 cells and macrophage RAW264.7 cells were cultured in DMEM containing 5% and 10% FBS, respectively. Treatments with troglitazone (1 µM), hexarelin, and GW9662 (Sigma, St. Louis, MO) were replaced with fresh medium every 24 h. To prepare oxLDL, LDLs (1.5 µg/ml) isolated from human plasma (Intracel, Frederick, MD) were oxidized with 5 µM CuSO4 for 2 h at 37 C. The extent of LDL oxidation ranged between 6 and 10 nmol malondialdehyde/mg of proteins as determined by the amount of thiobarbituric acid-reactive substances.

Lipid Staining
THP-1 cells were fixed with 3.7% formaldehyde/PBS and stained with Oil red O (Sigma). Quantification of lipid accumulation was achieved by extracting Oil red O from stained cells with isopropyl alcohol and measuring the OD of the extracts at 510 nm.

Cholesterol Efflux from Macrophages
THP-1 cells were differentiated as described above and labeled with 1 µCi/ml 3H-cholesterol for 48 h to allow for equilibration with cellular cholesterol. Cholesterol-loaded cells were washed and incubated in serum-free media containing 0.2% fatty acid free BSA, and efflux was initiated by adding 50 µg/ml HDL in the presence of 10–7 M hexarelin or vehicle. The amount of 3H-cholesterol was measured by liquid scintillation spectrometry in the medium and in the cell lysate (intracellular content) after 16 h of treatment. Cholesterol efflux is presented as specific percentage efflux calculated from total counts of the medium and intracellular fractions. Cholesterol efflux was also determined in peritoneal macrophage cells isolated from apoE-deficient mice (see below). Cells were incubated for 2 h at a density of 106 cells/well in DMEM containing 10% FBS and were washed to remove nonadherent cells before cholesterol efflux determination.

RNA Isolation and RT-PCR Analysis
Total RNA was isolated from THP-1 cells using TRIzol reagent (Invitrogen, Burlington, Ontario, Canada), and from mouse peritoneal macrophages using the RNeasy kit (QIAGEN Inc., Mississauga, Ontario, Canada), each according to the manufacturer’s protocol. RT-PCR analysis was performed as described (44), and relative signal intensities were determined with an image analyzer (Alpha Innotech, San Leandro, CA).

Antibodies and Immunoblotting Analysis
Antibodies to ABCA1 and ABCG1 were obtained from Novus Biologicals (Littleton, CO), PPAR{gamma} and LXR{alpha} were obtained from Santa Cruz Biotechnology (Santa Cruz, CA), and ß-actin was obtained from Abcam (Cambridge, MA). The antibody against CD36 has been described (19). Antibodies against GHS-R1a were generated by immunizing rabbits with a peptide corresponding to positions 250–262 of human GHS-R1a using a protocol described previously (18). The antiphosphoserine antibody was from Chemicon (Temecula, CA). Immunoprecipitation and immunoblotting procedures were performed as described (44, 56).

Luciferase Assay
For transient transfection, 293 cells were seeded in DMEM supplemented with 5% charcoal-dextran-treated FBS, and plasmid constructs were introduced into cells using the calcium phosphate precipitation method essentially as described (42). Typically, a mixture containing 500 ng of a PPREtkLuc reporter plasmid, 50–100 ng each of pCMX-hPPAR{gamma} and -hRXR{alpha}, and 100 ng pcDNA vector encoding human GHS-R1a or CD36 were added in a total of 2 µg per well. Cells were also transfected with pCMX encoding a Gal4 DBD fusion with PPAR{gamma} or with a LBD-truncated ABCD{gamma} (aa 1–254), and UAStkLuc reporter. Gal4 fusions with PPAR{alpha}, PPAR{delta}, LXR{alpha}, and LXRß were also used in transfection. RAW264.7 cells were transfected using LipofectAMINE reagent (Life Technologies Inc.) according to the manufacturer’s instructions. After transfection, cells were refed with medium containing receptor ligands for 16 h and were harvested for luciferase activity. Luciferase values were normalized for transfection efficiency to ß-galactosidase activity and expressed as relative fold response compared with controls. Luciferase assays were performed in duplicate in at least three independent experiments.

ChIP Assay
ChIP assays were performed as previously described (56). Differentiated THP-1 cells were grown at a density of 107/100-mm dish and were treated with troglitazone or hexarelin for 3 h. Cells were cross-linked with 1% formaldehyde, washed, and resuspended in sodium dodecyl sulfate lysis buffer. Lysates were then sonicated, clarified, and subjected to immunoprecipitation using an anti-PPAR{gamma} antibody (Santa Cruz Biotechnology). Specific genomic DNA fragments from immunoprecipitated samples and inputs were quantitated by PCR using 2–5 µl of sample DNA solution and primer pairs encompassing the PPRE-containing regions of CD36 (7) and LXR{alpha} (22) promoters.

Animals
Both apoE-deficient mice and wild-type C57Bl/6 littermates were previously described (43) and were given a standard pelleted diet with water ad libitum. At 6 wk of age, male mice were housed individually and maintained on a high-fat, high-cholesterol diet (D12108, cholate-free AIN-76A semi-purified diet containing 40% wt/wt fat and 1.25% wt/wt cholesterol; Research Diets Inc., New Brunswick, NJ) for 12 wk with water ad libitum. During that period, mice were treated with sc injections of 100 µg/kg·d hexarelin, a dose known to not promote GH release (16), or 0.9% NaCl (vehicle). Age-matched PPAR{gamma}+/– mice were maintained on standard diet with water ad libitum as described (27). All experimental procedures were carried out in accordance with the Institutional Animal Ethics Committee of the Université de Montréal, the Canadian Council on Animal Care guidelines, and the Cantonal Veterinary Service of the Canton of Vaud for use of experimental animals.

Macrophage Isolation and Foam Cell Assay
apoE-deficient mice were fed a high-cholesterol, high-fat diet for a period of 6 wk. Thioglycolate-elicited peritoneal macrophages were collected from both hexarelin-treated and control mice in saline containing 10 U heparin/ml. Peritoneal cells were cultured on sterile glass coverslip in DMEM containing 10% FBS. Adherent cells were incubated with 50 µg/ml oxLDL for 24 h, fixed in paraformaldehyde, and stained for neutral lipids with Oil red O. For RT-PCR analysis, apoE-null mice were maintained on a lipid-rich diet for a period of 12 wk and were treated daily with either saline or hexarelin. Before collection of macrophages, mice received an ip injection of oxLDL (250 µg/cavity) or 0.9% NaCl. RT-PCR was performed on macrophage RNA as described above. Expression studies were also performed on cultured peritoneal macrophages from age-matched wild-type C57Bl/6 and PPAR{gamma}+/– mice without prior thioglycolate stimulation and injection of oxLDL. Peritoneal cells were collected and cultured in DMEM containing 10% FBS for 2 h. Cells were then treated with hexarelin or saline for 24 h and harvested for RT-PCR and Western analyses.

Histology and Morphometric Analysis of Lesions
For en face analysis, the entire aortic section from hexarelin-treated and control mice was dissected out using a stereo-microscope (NI-150; Nikon, Melville, NY), opened longitudinally from the heart to the iliac arteries, and the lesions were stained with Oil red O, as described previously (43). Morphometric evaluation of the aortic lesion areas was performed using a video image analysis software (Scion Corp., Frederick, MD). Data are expressed as the percentage of the total aortic surface area covered by lesions for each treatment.


   ACKNOWLEDGMENTS
 
The authors thank Vincent Giguere and Maria Febbraio for providing plasmids. We also acknowledge the expert technical assistance of Eve Marie Charbonneau and Elisabeth Joye. Hexarelin was a generous gift from Europeptides (Argenteuil, France).


   FOOTNOTES
 
A.D. holds a doctoral award from the Canadian Institutes of Health Research (CIHR) and A.R.-W. is supported by a doctoral award from the Natural Sciences and Engineering Research Council of Canada. A.T. is a New Investigator of the CIHR. This work was supported by the CIHR, the Canadian Foundation for Innovation, the Swiss National Science Foundation, and Ardanna Bioscience (Edinburgh, Scotland, UK).

Present address for R.A.: Ricerca Farmacologica, Sanofi Midy Research Center, Sanofi-Synthelabo S.p.A., via Piranesi 38, 20137 Milano, Italy.

Disclosure statement: The authors have nothing to disclose.

First Published Online September 7, 2006

1 R.A. and A.D. contributed equally to this work. Back

Abbreviations: aa, Amino acids; ABC, ATP-binding cassette; AF, activation function; apoE, apolipoprotein E; ChIP, chromatin immunoprecipitation; FBS, fetal bovine serum; GHRP, GH-releasing peptide; GHS-R1a, GH secretagogue-receptor 1a; HDL, high-density lipoprotein; LDL, low-density lipoprotein; LXR, liver X receptor; oxLDL, oxidized LDL; PMA, phorbol myristate acetate; PPAR, peroxisome proliferator-activated receptor; PPRE, PPAR response element.

Received for publication March 31, 2006. Accepted for publication August 28, 2006.


   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 RESULTS
 DISCUSSION
 MATERIALS AND METHODS
 REFERENCES
 

  1. Ricote M, Valledor AF, Glass CK 2004 Decoding transcriptional programs regulated by PPARs and LXRs in the macrophage: effects on lipid homeostasis, inflammation, and atherosclerosis. Arterioscler Thromb Vasc Biol 24:230–239[Abstract/Free Full Text]
  2. Castrillo A, Tontonoz P 2004 Nuclear receptors in macrophage biology: at the crossroads of lipid metabolism and inflammation. Annu Rev Cell Dev Biol 20:455–480[CrossRef][Medline]
  3. Desvergne B, Michalik L, Wahli W 2004 Be fit or be sick: peroxisome proliferator-activated receptors are down the road. Mol Endocrinol 18:1321–1332[Abstract/Free Full Text]
  4. Pasceri V, Wu HD, Willerson JT, Yeh ET 2000 Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-{gamma} activators. Circulation 101:235–238[Abstract/Free Full Text]
  5. Chen Z, Ishibashi S, Perrey S, Osuga J, Gotoda T, Kitamine T, Tamura Y, Okazaki H, Yahagi N, Iizuka Y, Shionoiri F, Ohashi K, Harada K, Shimano H, Nagai R, Yamada N 2001 Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice: pleiotropic effects on CD36 expression and HDL. Arterioscler Thromb Vasc Biol 21:372–377[Abstract/Free Full Text]
  6. Li AC, Brown KK, Silvestre MJ, Willson TM, Palinski W, Glass CK 2000 Peroxisome proliferator-activated receptor {gamma} ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 106:523–531[Medline]
  7. Tontonoz P, Nagy L, Alvarez JGA, Thomazy VA, Evans RM 1998 PPAR{gamma} promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93:241–252[CrossRef][Medline]
  8. Nagy L, Tontonoz P, Alvarez JGA, Chen H, Evans RM 1998 Oxidized LDL regulates macrophage gene expression through ligand activation of PPAR{gamma}. Cell 93:229–240[CrossRef][Medline]
  9. Chawla A, Boisvert WA, Lee CH, Laffitte BA, Barak Y, Joseph SB, Liao D, Nagy L, Edwards PA, Curtiss LK, Evans RM, Tontonoz P 2001 A PPAR {gamma}-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 7:161–171[CrossRef][Medline]
  10. Laffitte BA, Repa JJ, Joseph SB, Wilpitz DC, Kast HR, Mangelsdorf DJ, Tontonoz P 2001 LXRs control lipid-inducible expression of the apolipoprotein E gene in macrophages and adipocytes. Proc Natl Acad Sci USA 98:507–512[Abstract/Free Full Text]
  11. Howard AD, Feighner SD, Cully DF, Arena JP, Liberator PA, Rosenblum CI, Hamelin M, Hreniuk DL, Palyha OC, Anderson J, Paress PS, Diaz C, Chou M, Liu KK, McKee KK, Pong SS, Chaung LY, Elbrecht A, Dashkevicz M, Heavens R, Rigby M, Sirinathsinghji DJ, Dean DC, Melillo DG, Van der Ploeg LH 1996 A receptor in pituitary and hypothalamus that functions in growth hormone release. Science 273:974–977[Abstract]
  12. Kojima M, Hosoda H, Matsuo H, Kangawa K 2001 Ghrelin: discovery of the natural endogenous ligand for the growth hormone secretagogue receptor. Trends Endocrinol Metab 12:118–122[CrossRef][Medline]
  13. Lazarczyk MA, Lazarczyk M, Grzela T 2003 Ghrelin: a recently discovered gut-brain peptide. Int J Mol Med 12:279–287[Medline]
  14. Marleau S, Mulumba M, Lamontagne D, Ong H 2006 Cardiac and peripheral actions of growth hormone and its releasing peptides: relevance for the treatment of cardiomyopathies. Cardiovasc Res 69:26–35[Abstract/Free Full Text]
  15. De Gennaro Colonna V, Rossoni G, Bernareggi M, Muller EE, Berti F 1997 Cardiac ischemia and impairment of vascular endothelium function in hearts from growth hormone-deficient rats: protection by hexarelin. Eur J Pharmacol 334:201–207[CrossRef][Medline]
  16. Locatelli V, Rossoni G, Schweiger F, Torsello A, De GC, V, Bernareggi M, Deghenghi R, Muller EE, Berti F 1999 Growth hormone-independent cardioprotective effects of hexarelin in the rat. Endocrinology 140:4024–4031[Abstract/Free Full Text]
  17. Torsello A, Bresciani E, Rossoni G, Avallone R, Tulipano G, Cocchi D, Bulgarelli I, Deghenghi R, Berti F, Locatelli V 2003 Ghrelin plays a minor role in the physiological control of cardiac function in the rat. Endocrinology 144:1787–1792[Abstract/Free Full Text]
  18. Bodart V, Febbraio M, Demers A, McNicoll N, Pohankova P, Perreault A, Sejlitz T, Escher E, Silverstein RL, Lamontagne D, Ong H 2002 CD36 mediates the cardiovascular action of growth hormone-releasing peptides in the heart. Circ Res 90:844–849[Abstract/Free Full Text]
  19. Demers A, McNicoll N, Febbraio M, Servant M, Marleau S, Silverstein R, Ong H 2004 Identification of the growth hormone-releasing peptide binding site in CD36: a photoaffinity cross-linking study. Biochem J 382:417–424[CrossRef][Medline]
  20. Li AC, Binder CJ, Gutierrez A, Brown KK, Plotkin CR, Pattison JW, Valledor AF, Davis RA, Willson TM, Witztum JL, Palinski W, Glass CK 2004 Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPAR{alpha}, ß/{delta}, and {gamma}. J Clin Invest 114:1564–1576[CrossRef][Medline]
  21. Gelman L, Michalik L, Desvergne B, Wahli W 2005 Kinase signaling cascades that modulate peroxisome proliferator-activated receptors. Curr Opin Cell Biol 17:216–222[CrossRef][Medline]
  22. Laffitte BA, Joseph SB, Walczak R, Pei L, Wilpitz DC, Collins JL, Tontonoz P 2001 Autoregulation of the human liver X receptor {alpha} promoter. Mol Cell Biol 21:7558–7568[Abstract/Free Full Text]
  23. Plump AS, Smith JD, Hayek T, Aalto-Setala K, Walsh A, Verstuyft JG, Rubin EM, Breslow JL 1992 Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell 71:343–353[CrossRef][Medline]
  24. Zhang SH, Reddick RL, Piedrahita JA, Maeda N 1992 Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science 258:468–471[Abstract/Free Full Text]
  25. Barak Y, Nelson MC, Ong ES, Jones YZ, Ruiz-Lozano P, Chien KR, Koder A, Evans RM 1999 PPAR {gamma} is required for placental, cardiac, and adipose tissue development. Mol Cell 4:585–595[CrossRef][Medline]
  26. Kubota N, Terauchi Y, Miki H, Tamemoto H, Yamauchi T, Komeda K, Satoh S, Nakano R, Ishii C, Sugiyama T, Eto K, Tsubamoto Y, Okuno A, Murakami K, Sekihara H, Hasegawa G, Naito M, Toyoshima Y, Tanaka S, Shiota K, Kitamura T, Fujita T, Ezaki O, Aizawa S, Kadowaki T 1999 PPAR {gamma} mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 4:597–609[CrossRef][Medline]
  27. Rieusset J, Seydoux J, Anghel SI, Escher P, Michalik L, Soon TN, Metzger D, Chambon P, Wahli W, Desvergne B 2004 Altered growth in male peroxisome proliferator-activated receptor {gamma} heterozygous mice: involvement of PPAR{gamma} in a negative feedback regulation of growth hormone action. Mol Endocrinol 18:2363–2377[Abstract/Free Full Text]
  28. Shalev A, Siegrist-Kaiser CA, Yen PM, Wahli W, Burger AG, Chin WW, Meier CA 1996 The peroxisome proliferator-activated receptor {alpha} is a phosphoprotein: regulation by insulin. Endocrinology 137:4499–4502[Abstract]
  29. Zhang B, Berger J, Zhou G, Elbrecht A, Biswas S, White-Carrington S, Szalkowski D, Moller DE 1996 Insulin- and mitogen-activated protein kinase-mediated phosphorylation and activation of peroxisome proliferator-activated receptor {gamma}. J Biol Chem 271:31771–31774[Abstract/Free Full Text]
  30. Werman A, Hollenberg A, Solanes G, Bjorbaek C, Vidal-Puig AJ, Flier JS 1997 Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor {gamma} (PPAR{gamma}). Differential activity of PPAR{gamma}1 and -2 isoforms and influence of insulin. J Biol Chem 272:20230–20235[Abstract/Free Full Text]
  31. Lazennec G, Canaple L, Saugy D, Wahli W 2000 Activation of peroxisome proliferator-activated receptors (PPARs) by their ligands and protein kinase A activators. Mol Endocrinol 14:1962–1975[Abstract/Free Full Text]
  32. Jimenez B, Volpert OV, Crawford SE, Febbraio M, Silverstein RL, Bouck N 2000 Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. Nat Med 6:41–48[CrossRef][Medline]
  33. Moore KJ, El Khoury J, Medeiros LA, Terada K, Geula C, Luster AD, Freeman MW 2002 A CD36-initiated signaling cascade mediates inflammatory effects of ß-amyloid. J Biol Chem 277:47373–47379[Abstract/Free Full Text]
  34. Kim MS, Yoon CY, Jang PG, Park YJ, Shin CS, Park HS, Ryu JW, Pak YK, Park JY, Lee KU, Kim SY, Lee HK, Kim YB, Park KS 2004 The mitogenic and antiapoptotic actions of ghrelin in 3T3-L1 adipocytes. Mol Endocrinol 18:2291–2301[Abstract/Free Full Text]
  35. Mazzocchi G, Neri G, Rucinski M, Rebuffat P, Spinazzi R, Malendowicz LK, Nussdorfer GG 2004 Ghrelin enhances the growth of cultured human adrenal zona glomerulosa cells by exerting MAPK-mediated proliferogenic and antiapoptotic effects. Peptides 25:1269–1277[CrossRef][Medline]
  36. Nanzer AM, Khalaf S, Mozid AM, Fowkes RC, Patel MV, Burrin JM, Grossman AB, Korbonits M 2004 Ghrelin exerts a proliferative effect on a rat pituitary somatotroph cell line via the mitogen-activated protein kinase pathway. Eur J Endocrinol 151:233–240[Abstract]
  37. Brywe KG, Leverin AL, Gustavsson M, Mallard C, Granata R, Destefanis S, Volante M, Hagberg H, Ghigo E, Isgaard J 2005 Growth hormone-releasing peptide hexarelin reduces neonatal brain injury and alters Akt/glycogen synthase kinase-3ß phosphorylation. Endocrinology 146:4665–4672[Abstract/Free Full Text]
  38. Adams M, Reginato MJ, Shao D, Lazar MA, Chatterjee VK 1997 Transcriptional activation by peroxisome proliferator-activated receptor {gamma} is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site. J Biol Chem 272:5128–5132[Abstract/Free Full Text]
  39. Camp HS, Tafuri SR 1997 Regulation of peroxisome proliferator-activated receptor {gamma} activity by mitogen-activated protein kinase. J Biol Chem 272:10811–10816[Abstract/Free Full Text]
  40. Shao D, Rangwala SM, Bailey ST, Krakow SL, Reginato MJ, Lazar MA 1998 Interdomain communication regulating ligand binding by PPAR-{gamma}. Nature (Lond) 396:377–380[CrossRef][Medline]
  41. Han J, Hajjar DP, Tauras JM, Feng J, Gotto Jr AM, Nicholson C 2000 Transforming growth factor-ß1 (TGF-ß1) and TGF-ß2 decrease expression of CD36, the type B scavenger receptor, through mitogen-activated protein kinase phosphorylation of peroxisome proliferator-activated receptor-{gamma}. J Biol Chem 275:1241–1246[Abstract/Free Full Text]
  42. Tremblay A, Tremblay GB, Labrie F, Giguere V 1999 Ligand-independent recruitment of SRC-1 to estrogen receptor ß through phosphorylation of activation function AF-1. Mol Cell 3:513–519[CrossRef][Medline]
  43. Febbraio M, Podrez EA, Smith JD, Hajjar DP, Hazen SL, Hoff HF, Sharma K, Silverstein RL 2000 Targeted disruption of the class B scavenger receptor CD36 protects against atherosclerotic lesion development in mice. J Clin Invest 105:1049–1056[Medline]
  44. Marleau S, Harb D, Bujold K, Avallone R, Iken K, Wang Y, Demers A, Sirois M, Febbraio M, Silverstein M, Tremblay A, Ong H 2005 EP80317, a ligand of the CD36 scavenger receptor, protects apolipoprotein E-deficient mice from developing atherosclerotic lesions. FASEB J 19:1869–1871[Abstract/Free Full Text]
  45. Nakata A, Nakagawa Y, Nishida M, Nozaki S, Miyagawa J, Nakagawa T, Tamura R, Matsumoto K, Kameda-Takemura K, Yamashita S, Matsuzawa Y 1999 CD36, a novel receptor for oxidized low-density lipoproteins, is highly expressed on lipid-laden macrophages in human atherosclerotic aorta. Arterioscler Thromb Vasc Biol 19:1333–1339[Abstract/Free Full Text]
  46. Akiyama TE, Sakai S, Lambert G, Nicol CJ, Matsusue K, Pimprale S, Lee YH, Ricote M, Glass CK, Brewer Jr HB, Gonzalez FJ 2002 Conditional disruption of the peroxisome proliferator-activated receptor {gamma} gene in mice results in lowered expression of ABCA1, ABCG1, and apoE in macrophages and reduced cholesterol efflux. Mol Cell Biol 22:2607–2619[Abstract/Free Full Text]
  47. Yesner LM, Huh HY, Pearce SF, Silverstein RL 1996 Regulation of monocyte CD36 and thrombospondin-1 expression by soluble mediators. Arterioscler Thromb Vasc Biol 16:1019–1025[Abstract/Free Full Text]
  48. Hsu HY, Nicholson AC, Hajjar DP 1996 Inhibition of macrophage scavenger receptor activity by tumor necrosis factor-{alpha} is transcriptionally and post-transcriptionally regulated. J Biol Chem 271:7767–7773[Abstract/Free Full Text]
  49. Liang CP, Han S, Okamoto H, Carnemolla R, Tabas I, Accili D, Tall AR 2004 Increased CD36 protein as a response to defective insulin signaling in macrophages. J Clin Invest 113:764–773[CrossRef][Medline]
  50. Gnanapavan S, Kola B, Bustin SA, Morris DG, McGee P, Fairclough P, Bhattacharya S, Carpenter R, Grossman AB, Korbonits M 2002 The tissue distribution of the mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol Metab 87:2988[Abstract/Free Full Text]
  51. Choi K, Roh SG, Hong YH, Shrestha YB, Hishikawa D, Chen C, Kojima M, Kangawa K, Sasaki S 2003 The role of ghrelin and growth hormone secretagogues receptor on rat adipogenesis. Endocrinology 144:754–759[Abstract/Free Full Text]
  52. Granado M, Priego T, Martin AI, Villanua MA, Lopez-Calderon A 2005 Anti-inflammatory effect of the ghrelin agonist growth hormone-releasing peptide-2 (GHRP-2) in arthritic rats. Am J Physiol Endocrinol Metab 288:E486–E492
  53. Li WG, Gavrila D, Liu X, Wang L, Gunnlaugsson S, Stoll LL, McCormick ML, Sigmund CD, Tang C, Weintraub NL 2004 Ghrelin inhibits proinflammatory responses and nuclear factor-{kappa}B activation in human endothelial cells. Circulation 109:2221–2226[Abstract/Free Full Text]
  54. Lee CH, Chawla A, Urbiztondo N, Liao D, Curtiss LK, Boisvert WA, Evans RM 2003 Transcriptional repression of atherogenic inflammation: modulation by PPAR{delta}. Science 302:453–457[Abstract/Free Full Text]
  55. Welch JS, Ricote M, Akiyama TE, Gonzalez FJ, Glass CK 2003 PPAR{gamma} and PPAR{delta} negatively regulate specific subsets of lipopolysaccharide and IFN-{gamma} target genes in macrophages. Proc Natl Acad Sci USA 100:6712–6717[Abstract/Free Full Text]
  56. St Laurent V, Sanchez M, Charbonneau C, Tremblay A 2005 Selective hormone-dependent repression of estrogen receptor ß by a p38-activated ErbB2/ErbB3 pathway. J Steroid Biochem Mol Biol 94:23–37[CrossRef][Medline]

NURSA Molecule Pages Link:

Nuclear Receptors:   PPARα  |  PPARδ  |  PPARγ  |  LXRβ  |  LXRα  |  RXRα
Ligands:   22α-Hydroxycholesterol  |  GW 9662  |  Pirinixic acid



This article has been cited by other articles:


Home page
 Cardiovasc ResHome page
K. Bujold, D. Rhainds, C. Jossart, M. Febbraio, S. Marleau, and H. Ong
CD36-mediated cholesterol efflux is associated with PPAR{gamma} activation via a MAPK-dependent COX-2 pathway in macrophages
Cardiovasc Res, August 1, 2009; 83(3): 457 - 464.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
D. P. Ramji
Growth hormone-releasing peptides, CD36, and stimulation of cholesterol efflux: cyclooxygenase-2 is the link
Cardiovasc Res, August 1, 2009; 83(3): 419 - 420.
[Full Text] [PDF]

Home page
 Cancer Res.Home page
K. Sauve, J. Lepage, M. Sanchez, N. Heveker, and A. Tremblay
Positive Feedback Activation of Estrogen Receptors by the CXCL12-CXCR4 Pathway
Cancer Res., July 15, 2009; 69(14): 5793 - 5800.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
D. Harb, K. Bujold, M. Febbraio, M. G. Sirois, H. Ong, and S. Marleau
The role of the scavenger receptor CD36 in regulating mononuclear phagocyte trafficking to atherosclerotic lesions and vascular inflammation
Cardiovasc Res, July 1, 2009; 83(1): 42 - 51.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
A. Tesse, G. Al-Massarani, R. Wangensteen, S. Reitenbach, M. C. Martinez, and R. Andriantsitohaina
Rosiglitazone, a Peroxisome Proliferator-Activated Receptor-{gamma} Agonist, Prevents Microparticle-Induced Vascular Hyporeactivity through the Regulation of Proinflammatory Proteins
J. Pharmacol. Exp. Ther., February 1, 2008; 324(2): 539 - 547.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
A. Rodrigue-Way, A. Demers, H. Ong, and A. Tremblay
A Growth Hormone-Releasing Peptide Promotes Mitochondrial Biogenesis and a Fat Burning-Like Phenotype through Scavenger Receptor CD36 in White Adipocytes
Endocrinology, March 1, 2007; 148(3): 1009 - 1018.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
M. Iantorno, H. Chen, J.-a Kim, M. Tesauro, D. Lauro, C. Cardillo, and M. J. Quon
Ghrelin has novel vascular actions that mimic PI 3-kinase-dependent actions of insulin to stimulate production of NO from endothelial cells
Am J Physiol Endocrinol Metab, March 1, 2007; 292(3): E756 - E764.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Sanchez, K. Sauve, N. Picard, and A. Tremblay
The Hormonal Response of Estrogen Receptor beta Is Decreased by the Phosphatidylinositol 3-Kinase/Akt Pathway via a Phosphorylation-dependent Release of CREB-binding Protein
J. Biol. Chem., February 16, 2007; 282(7): 4830 - 4840.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow NURSA Molecule Pages Link
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Avallone, R.
Right arrow Articles by Tremblay, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Avallone, R.
Right arrow Articles by Tremblay, A.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals